US · Healthcare · Diagnostics & Research
EPS came in at 3.47 against a street estimate of 3.41 — a beat of 1.8%.
Analysts rate IDEXX Laboratories Inc a buy (6 buy, 6 hold, 1 sell out of 13) with an average price target of $707.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.61% |
| Vanguard Capital Management, LLC | 6.57% |
| Vanguard Portfolio Management, LLC | 4.96% |
| State Street Corp | 4.66% |
| Amvescap Plc. | 4.25% |
| Geode Capital Management, LLC | 3.37% |
| BAMCO Inc | 2.07% |
| Bank of New York Mellon Corp | 1.91% |
| Document | Date |
|---|---|
| Charter / bylaws change · Q2 2026 | 2026-05-15 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q4 2025 | 2026-03-27 |
| Board / officer change · Q1 2026 | 2026-03-26 |
| Annual report FY2025 | 2026-02-20 |
| Board / officer change · Q1 2026 | 2026-02-13 |
| Quarterly report · Q3 2025 | 2025-11-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for IDEXX Laboratories Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.